(Q45272404)

11 December 2017

Switch from cyclosporine A to mycophenolate mofetil in nephrotic children (English)

1 reference

11 December 2017

1 reference

Tim Ulinski

1

1 reference

11 December 2017

Laurence Dubourg

2

1 reference

11 December 2017

Marie Hélène Saïd

3

1 reference

11 December 2017

Bernadette Parchoux

4

1 reference

11 December 2017

Bruno Ranchin

5

1 reference

11 December 2017

Pierre Cochat

6

1 reference

11 December 2017

18 February 2005

1 reference

11 December 2017

1 reference

11 December 2017

20

1 reference

11 December 2017

4

1 reference

11 December 2017

482-485

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-004-1778-4

11 December 2017

0 references

cites work

The design and development of an immunosuppressive drug, mycophenolate mofetil

1 reference

12 December 2020

Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney

1 reference

12 December 2020

Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade

1 reference

12 December 2020

Long-term clinical and pathological effects of cyclosporin in children with nephrosis

1 reference

12 December 2020

Pharmacological regulation of the immune system

1 reference

12 December 2020

Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil

1 reference

12 December 2020

Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines

1 reference

12 December 2020

Lymphocyte-selective antiproliferative and immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents

1 reference

12 December 2020

Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells.

1 reference

12 December 2020

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

1 reference

12 December 2020

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome

1 reference

12 December 2020

Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules

1 reference

12 December 2020

Immunosuppressive and other anti-rheumatic activities of mycophenolate mofetil

1 reference

12 December 2020

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

12 December 2020

Brequinar sodium, mycophenolic acid, and cyclosporin A inhibit different stages of IL-4- or IL-13-induced human IgG4 and IgE production in vitro.

1 reference

12 December 2020

Mycophenolate mofetil prevents the induction of active Heymann nephritis: association with Th2 cytokine inhibition

1 reference

12 December 2020

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

1 reference

12 December 2020

10.1007/S00467-004-1778-4

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

0 references

1 reference